ENVB · XBRL financial data

Enveric Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ENVB's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,352	1,369*	458	516	763	1,105*	746	1,260	402	372*	346	1,355
General and administrative	2,010	931*	1,934	1,298	1,236	1,986*	1,360	1,219	1,431	1,782*	1,250	1,635
Total operating expenses	—	—	—	—	—	—	—	2,519	—	—	—	3,027
Operating income (loss)	(3,448)	(2,384)*	(2,477)	(1,898)	(2,083)	(3,174)*	(2,188)	(2,519)	(1,874)	(2,194)*	(1,633)	(3,027)
Other income (expense)	—	—	—	—	(1)	—	—	—	—	—	—	—
Income tax expense (benefit)	7	22*	2	0*	0*	7*	—	—	—	—	—	—
Net income (loss)	(2,822)	(3,436)*	(2,457)	(1,879)	(2,084)	(3,155)*	(2,185)	(2,519)	(1,874)	(2,194)*	(1,633)	(3,028)
Earnings per share, basic USD per share	(1.30)	(1.50)*	(0.61)	(0.25)	(0.24)	—	(1.22)	(0.97)	(10.81)	—	(1.08)	(0.76)
Earnings per share, diluted USD per share	(1.30)	(1.50)*	(0.61)	(0.25)	(0.24)	—	(1.22)	(0.97)	(10.81)	—	(1.08)	(0.76)
Weighted average shares, basic thousands of shares	2,165	2,283*	4,001	7,588	8,703	—	1,798	2,596	313	—	1,510	3,987
Weighted average shares, diluted thousands of shares	2,165	2,283*	4,001	7,588	8,703	—	1,798	2,596	313	—	1,510	3,987

† Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 2x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ENVB's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	4,267	2,288	6,356	3,503	3,112	2,241	4,294	2,850	3,758	4,677	4,909	8,296
Prepaid and other current assets	1,560	1,294	1,873	2,017	1,227	494	540	458	408	259	466	497
Total current assets	5,827	3,582	8,229	5,520	4,338	2,735	4,835	3,307	4,166	4,937	5,375	8,793
Property and equipment, net	539	507	452	405	368	306	267	241	197	159	120	82
Goodwill	253	—	—	—	—	—	—	—	—	—	—	—
Total assets	6,619	4,300	8,850	6,052	4,790	3,083	5,102	3,548	4,362	5,096	5,521	8,944
Accounts payable	1,098	1,219	1,853	460	576	522	669	1,041	684	581	280	683
Accrued liabilities	1,534	1,076	487	176	253	732	414	223	222	238	180	152
Total current liabilities	4,184	2,344	2,368	645	839	1,490	1,184	1,364	906	918	461	861
Accumulated deficit	(93,064)	(96,500)	(98,956)	(100,836)	(102,920)	(106,075)	(108,259)	(110,779)	(112,652)	(114,846)	(116,480)	(119,508)
Total stockholders' equity	2,436	1,956	6,482	5,406	3,951	1,593	3,918	2,185	3,456	4,178	5,061	8,083
Total liabilities and equity	6,619	4,300	8,850	6,052	4,790	3,083	5,102	3,548	4,362	5,096	5,521	8,944
Common shares outstanding (cover page) thousands of shares	2,321	7,294	7,752	8,920	9,945	2,472	2,472	3,246	597	1,888	3,682	4,476

† Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 2x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ENVB's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,822)	(3,436)*	(2,457)	(1,879)	(2,084)	(3,155)*	(2,185)	(2,519)	(1,874)	(2,194)*	(1,633)	(3,028)
Stock-based compensation	373*	365*	351	370*	370*	472*	194	206*	187*	240*	89	125*
Net cash from operating activities	(2,740)*	(1,751)*	(2,598)	(2,889)*	(927)*	(1,312)*	(2,392)	(1,890)*	(2,075)*	(1,785)*	(2,257)	(2,445)*
Purchases of property and equipment	0*	(0)*	—	—	—	—	—	—	—	—	—	—
Net cash from investing activities	0*	(0)*	—	—	—	—	—	—	—	—	—	—
Proceeds from issuing common stock	—	—	2,308	(18)*	0*	0*	—	—	—	—	1,298	(7)*
Net cash from financing activities	(105)*	(186)*	6,658	34*	518*	463*	4,449	449*	2,992*	2,689*	2,503	5,845*
Net change in cash	(2,815)*	(1,979)*	4,068	(2,853)*	(391)*	(871)*	2,053	(1,445)*	908*	920*	231	3,388*

† Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 2x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Enveric Biosciences	8,296	not reported	(2,445)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	308	not reported	(1,819)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
Jaguar Health	3,788	1,225	(5,338)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Theriva Biologics	11,337	0*	(3,085)*	45.9M	3.7 quarters	Q2 FY26 10-QJun 30, 2026
Inhibitor Therapeutics	516	not reported	(775)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Healthy Extracts	190	2,067	306*	14.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.